Navigation Links
Crucell in Medical News

PATH Malaria Vaccine Initiative and Crucell to test new malaria vaccine approach

LEIDEN, The Netherlands, July 29, 2009 The US-based PATH Malaria Vaccine Initiative (MVI), the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP), and Dutch biopharmaceutical company Crucell N.V. today announced a collaboration to accelerate deve...

DSM and Crucell Sign Agreement with Avid Bioservices to Serve as First Pre-Approved U.S. Contract Manufacturer of PER.C6(R) Cell Line Proteins

LEIDEN, Netherlands and PARSIPPANY, N.J., June 25 /PRNewswire/ -- DSM Biologics and Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) announced today that they have entered into an agreement with Avid Bioservices, Inc. of Tustin, California to join their Vendor Network. Under the term...

Sanofi Pasteur Enters Agreement With Crucell for Next-Generation Biologicals Against Rabies

Exclusive Agreement for Rabies Monoclonal Antibodies to Fight Fatal Disease LYON, France, January 3 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has signed an exclusive collaboration and commercialization agreement with Crucell ...

Flu virus foiled again

...ersal influenza vaccine. The Scripps research team, led by Ian A. Wilson, Ph.D., in collaboration with researchers at the biopharmaceutical company crucell Holland (The Netherlands), discovered the potent antibody during a systematic examination of blood samples taken from healthy individuals who previous...

Boston Trial to Test New HIV/AIDS Vaccine

...V/AIDS vaccine candidates. The vaccine, the first HIV-1 vaccine candidate to emerge from the IPCAVD program, is made by Dutch biotechnology company crucell Holland B.V. The approach used in developing the rAd26 vaccine enables researchers to circumvent preexisting immunity to serotype 5, the virus resp...

Clinical trial will test new HIV/AIDS vaccine

...sion of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health. Manufactured by the Dutch biotechnology company crucell Holland BV, the rAd26 vaccine is the first HIV-1 vaccine candidate to emerge from the IPCAVD initiative, which brings together investigators from acad...

Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Proposed Dividend

...f alliance agreements with Regeneron, Acambis, crucell and Oxford Biomedica, and buyout of rights to ...ron, Oxford BioMedica (TroVax(R)), UCB (Xyzal(R)), crucell N.V. and Acambis. Acquisitions of investments (e...I (to develop a new tuberculosis vaccine) and with crucell (in monoclonal rabies antibodies), plus an allianc...

Crucell's Rabies MAb Enters Phase I Trial in India

... Dutch biotechnology company, crucell N V’s Rabies monoclonal antibody (mAb) product has entered a phase I clinical study in India, four months after launching// a similar study in the US....
Crucell in Medical Technology

Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa

ATLANTA, April 9, 2008 /PRNewswire-USNewswire/ -- Dutch biotechnology company Crucell N.V., the Aeras Global TB Vaccine Foundation and the South African Tuberculosis Vaccine Initiative (SATVI) present a progress update and immunology data from a Phase I Ad35 tuberculosis vaccine study at th...

ProFibrix Steps up Recombinant Fibrinogen Program With PER.C6(R) License From Crucell

LEIDEN, The Netherlands, January 13 /PRNewswire/ -- ProFibrix B.V., today announced that it has concluded a commercial license agreement with Crucell N.V. (Euronext, NASDAQ: CRXL ; Swiss Exchange: CRX) for PER.C6(R), a unique human protein production platform. The PER.C6(R) platform allows P...

DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms

... In addition to offering world-class biopharmaceutical manufacturing services, DSM Biologics has co-exclusive rights, along with Dutch biotech company crucell N.V., to license the high-producing PER.C6(R) human cell line as a production platform for recombinant proteins and monoclonal antibodies. The combina...

Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine

...l line, licensed from Dutch biotechnology company, crucell N.V. PER.C6 Cell technology offers Sanofi Pasteur ...ion can be found at http://www.lonza.com . About crucell crucell N.V. is a Dutch biotechnology company (Euronext, N...
Crucell in Biological Technology

DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins

LEIDEN, The Netherlands, and PARSIPPANY, N.J., Feb. 10 /PRNewswire/ -- DSM Biologics and Crucell N.V. (Euronext, Nasdaq: CRXL ; Swiss Exchange: CRX) announced today that they have entered into an agreement with Bioceros B.V. of Utrecht, The Netherlands to join their Vendor Network. Under the ter...

DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter

PARSIPPANY, N.J. and LEIDEN, Netherlands, Nov. 25 /PRNewswire/ -- DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biotechnology company Crucell N.V. (Euronext, Nasdaq: CRXL ; Swiss Exchange: CRX), today announced that Hungary-based Gedeon Richter Plc. signed a commercial...

DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters

GRONINGEN and LEIDEN, Netherlands and PARSIPPANY, N.J., Sept. 29 /PRNewswire/ -- DSM Biologics and Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) announced today that the high-titer fed-batch process developed at the PERCIVIA PER.C6(R) Development Center, their joint venture in Camb...

World Nanomedicine Market to Cross $160 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

...ayers. Major market participants in the nanomedicine market include Abraxis BioScience Inc., AMAG Pharmaceuticals Inc, Arrowhead Research Corporation, crucell N.V., Flamel Technologies S.A., Elan Corporation Plc, Enzon Pharmaceuticals Inc., Life Technologies Corporation, Nanosphere Inc., Nektar Therapeutics,...

KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)

...hon added, "Our KBI scientific team has extensive experience producing cell lines in microbial, insect and mammalian systems and are very pleased that crucell and DSM have recognized our expertise by selecting KBI as a Partner for their Vendor Network." KBI is now proud to offer the PER.C6(R) technolog...

Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009

...ain cancer. Other Developments -- Avid Bioservices became the first U.S. pre-approved contract manufacturer for licensees of the DSM Biologics and crucell PER.C6(R) cell line, a proprietary high yield cell line with important advantages over other approaches. -- Received a Staff Determination letter fr...

DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody

...exclusive rights, along with Dutch biotech company crucell N.V., to license the high-producing PER.C6(R) huma...hat are difficult to predict and therefore DSM and crucell do not guarantee that their expectations will be realized. Furthermore, DSM and crucell have no obligation to update the statements contai...
Other Tags
(Date:5/4/2015)... York, NY (PRWEB) May 04, 2015 ... specialized insurance programs, announces the expansion of coverage for ... is a leading provider of industry-tailored insurance and proactive ... McNeil & Company, we are dedicated to providing our ... to meet their many evolving needs. We are excited ...
(Date:5/4/2015)... Healthcare Solutions is proud to be a sponsor at ... in Baltimore, MD from May 11 – 13, 2015. ... opportunity for clients to gather to network, attend educational ... to sponsoring the event, TROY Healthcare Solutions will be ... can stop by the TROY booth and see sample ...
(Date:5/4/2015)... 2015 Baptist Medical Center Jacksonville ... Get With The Guidelines®-Stroke Gold Plus Quality Achievement ... The award recognizes the hospital’s commitment and success ... appropriate treatment according to nationally recognized, research-based guidelines ... receive the Gold Plus Quality Achievement Award, hospitals ...
(Date:5/4/2015)... Now in its seventh year, the IPC ... made outstanding contributions to the company, to their facilities ... and post-acute care settings. The five award categories are: ... Year, Advanced Practice Clinician of the Year, Newcomer Provider ... Recipients are selected by IPC’s senior management team. , ...
(Date:5/4/2015)... Los Angeles, CA (PRWEB) May 04, 2015 ... Kevin Sands, is now offering a more comfortable and ... been the restoration of choice for those who have ... patients. Dentures can feel insecure or slip at the ... the patient eats or talks. They can also painfully ...
Breaking Medicine News(10 mins):Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2
(Date:4/17/2015)... 2015 Increasing adoption ... advancement to drive biometric systems market in ... According to a recently released TechSci ... ", biometric systems market in Saudi ... at CAGR of over 22% through 2020. The ...
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2
Other Contents